France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases
RNAi-Focused Atalanta Therapeutics Launches
Alzheimer’s Disease, Biogen, Business, CNS Disorders, Collaborations, Company Launches, Deals, Financing, Genentech, Huntington’s disease, Neurodegenerative Diseases, Parkinson’s disease, RNA Interference (RNAi), RNAi therapeutics, Series A, Small Interfering RNA (siRNA)RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Roche company Genentech to identify and advance novel RNA-targeted small molecule therapeutics.
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Chemo Drug Potentially More Potent than Remdesivir Against Coronavirus
Antibiotics, Chemotherapeutics, Chemotherapy, China, Clinical Studies, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Drug screenings, Peripheral T-Cell Lymphoma (PTCL), PLOS Computational Biology, R&D, Remdesivir, Researchers, RNA, SARS-CoV-2 virus, TherapeuticsThe chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
Remix Therapeutics officially launched with $81 million in financing, with the funds to be used to support the development of the company’s REMaster technology platform while advancing a pipeline of RNA processing targeted therapeutics.
Q&A with Ogilvy Health’s Kate Cronin
Black Lives Matter, Business, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Vaccines, Digital, Healthcare, Healthcare Communications Agencies, Healthcare Physicians, Heart Health, Joe Biden, Marketing & Advertising, Med Ad News, Mental Health, Politics, RNA, Telehealth, Trends, U.S. government, Virtual Reality, WellnessKate Cronin, Global CEO of Ogilvy Health, shares her views on a variety of healthcare industry topics in a Q&A with PharmaLive.
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
AI Can Detect Covid-19 by Analyzing Coughs and More Related Research
ACE2 (angiotensin-converting enzyme-2), Antibodies, Artificial Intelligence, Blood Samples, Brigham and Women's Hospital, Cells, Children, Coronavirus Disease 2019 (COVID-19), Cough, Massachusetts Institute of Technology (MIT), Mouth, R&D, Researchers, RNA, Science Translational MedicineResearchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.